Pira3 Inhibitors
Pira3 inhibitors encompass a range of chemical compounds that interact with various signaling pathways, ultimately leading to the reduced functional activity of Pira3. Phosphoinositide 3-kinase (PI3K) inhibitors, such as Wortmannin and LY294002, exert their effects by diminishing PI3K activity, thereby disrupting the PI3K/Akt pathway that may be critical for Pira3 activation. Similarly, MAPK pathway inhibitors like U0126 and PD98059, which target MEK1/2, as well as SB203580, a selective p38 MAPK inhibitor, and SP600125, a JNK inhibitor, can attenuate pathways that potentially regulate or are regulated by Pira3. In doing so, these inhibitors prevent the phosphorylation and activation events that would typically enhance the functional activity of Pira3.
Additional compounds such as Rapamycin, an mTOR pathway inhibitor, and Bortezomib, a proteasome inhibitor, can also lead to decreased Pira3 activity by inhibiting crucial regulatory pathways or preventing the degradation of proteins that inhibit Pira3. Tyrosine kinase inhibitors like Dasatinib, Sorafenib, and Axitinib target various kinases that may act upstream of Pira3. By doing so, they can block the activation signals that would otherwise contribute to Pira3's functional state.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), Wortmannin leads to a decrease in PI3K activity, which can indirectly inhibit Pira3 by disrupting downstream signaling events that are essential for Pira3 activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Like Wortmannin, LY294002 is another PI3K inhibitor that impedes the PI3K/Akt pathway, a mechanism that would result in the reduced activity of Pira3 due to the suppression of the pathway that contributes to its activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound is a selective inhibitor of p38 MAPK. Inhibition of p38 MAPK can impact Pira3 activity by altering stress response pathways where Pira3 might be involved, thus decreasing its functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 can decrease Pira3 activity by interfering with JNK signaling pathways that Pira3 may regulate or be regulated by. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which can lead to the inhibition of the ERK pathway. As Pira3 activity could be dependent on ERK signaling, this inhibitor might lead to a decrease in Pira3 functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
As an mTOR inhibitor, Rapamycin can lead to the inhibition of the mTOR signaling pathway, which may be crucial for Pira3 function. Inhibition of mTOR could result in decreased Pira3 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinases are involved in various signaling pathways, and inhibition by PP2 may impact Pira3 activity if Pira3 is downstream or associated with Src-mediated signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which blocks the MAPK/ERK pathway. If Pira3 operates within this pathway, its functional activity would be diminished through the action of PD98059. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor, Bortezomib could indirectly inhibit Pira3 by preventing the degradation of regulatory proteins that suppress Pira3 activity or are required for its inactivation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that targets BCR-ABL and Src family kinases. If Pira3 is activated by these kinases, Dasatinib could inhibit Pira3 activity by blocking their function. | ||||||